1. Drossman D.A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV // Section I: fgids: background information functional gi overview. 2016. Vol. 150. Issue 6. P. 1262–1279.E2. DOI: 10.1053/j.gastro.2016.02.032.
2. Sperber A.D. et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study // Gastroenterol. 2021. Vol. 160. N. 1. P. 99–114.e3.
3. Barbara G. et al. Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome // Gastroenterol. 2019. Vol. 156. N. 1. P. 46––58.e7; Primers. 2016. Vol. 2. P. 16014.
8. Ивашкин В.Т., Маев И.В., Шелыгин Ю.А. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России «Диагностика и лечение синдрома раздраженного кишечника» // Рос. журн. гастроэнтерол. гепатол. колопроктол. 2021. Т. 31. №5. С. 74–95.
9. Wang C., Fang Х. Inflammation and Overlap of Irritable Bowel Syndrome and Functional Dyspepsia // J. Neurogastroenterol. Motility. 2021. Vol. 27. N. 2. P. 153–164.
10. Moraru I.G. et al. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania // Romanian J. Internal. Med. // Revue Roumaine De Medecine Interne. 2014. Vol. 52. N. 3. P. 143–150.
11. Ghoshal U.C. et al. A meta-analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome // J. Gastroenterol. Hepatol. 2020. Vol. 35. N. 6. P. 922–931.
12. David L., Babin A., Picos A., Dumitrascu D.L. Small Intestinal Bacterial Overgrowth is Associated with Intestinal Inflammation in the Irritable Bowel Syndrome // Clujul. Med. 2014. Vol. 87. N. 3. P. 163–165. DOI: 10.15386/cjmed-303.
13. Drossman D.A. et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator // Gastroenterol. 2005. Vol. 128. N. 3. P. 580–589.
14. Törnblom Н. et al. Colonic transit time and IBS symptoms: what’s the link? // Am. J. Gastroenterol. 2012. Vol. 107. N. 5. P. 754–760.
15. Lam С. et al. Distinct Abnormalities of Small Bowel and Regional Colonic Volumes in Subtypes of Irritable Bowel Syndrome Revealed by MRI // Am. J. Gastroenterol. 2017. Vol. 112. N. 2. P. 346–355.
16. Shussman N., Wexner S.D. Colorectal polyps and polyposis syndromes // Gastroenterol. Report. 2014. Vol. 2. N. 1. P. 1–15.
17. El-Salhy М. et al. Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment // Exp. Rev. Gastroenterol. Hepatol. 2014. Vol. 8. N. 4. P. 435–443.
18. Ohlsson B. Extraintestinal manifestations in irritable bowel syndrome: A systematic review // Ther. Adv. Gastroenterol. 2022. Vol. 15. P. 17562848221114558.
19. Whitehead W.E., Palsson О., Jones K.R. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? // Gastroenterol. 2002. Vol. 122. N. 4. P. 1140–1156.
20. Свистунов А.А. и др. Римские критерии синдрома раздраженного кишечника IV пересмотра (2016): что нового? // Клиническая Медицина. 2017. Т. 95. № 11. С. 987–993.
21. Halpert A., Godena Е. Irritable bowel syndrome patients’ perspectives on their relationships with healthcare providers // Scand. J. Gastroenterol. 2011. Vol. 46. N. 7–8. P. 823–830.
22. Bertram S. et al. The patient’s perspective of irritable bowel syndrome // J. Family Prac. 2001. Vol. 50. N. 6. P. 521–525.
23. Black C.J., Ford А.С. Best management of irritable bowel syndrome // Front. Gastroenterol. 2021. Vol. 12. N. 4. P. 303–315.
24. Hookway С. et al. Irritable bowel syndrome in adults in primary care: summary of updated NICE guidance // BMJ (Clin. Res. ed.). 2015. Vol. 350. P. h701.
25. Dancey C.P., Taghavi М., Fox R.J. The relationship between daily stress and symptoms of irritable bowel: a time-series approach // J. Psychosom. Res. 1998. Vol. 44. N. 5. P. 537–545.
26. Dossett M.L., Cohen Е.М., Cohen J. Integrative Medicine for Gastrointestinal Disease // Primary care. 2017. Vol. 44. N. 2. P. 265–280.
27. Chapman R.W. et al. Randomized clinical trial: macrogol / PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome // Am. J. Gastroenterol. 2013. Vol. 108. N. 9. P. 1508–1515.
28. Miner Р. et al. Plecanatide, a Novel Uroguanylin Analog: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate Efficacy and Safety in Patients With Irritable Bowel Syndrome With Constipation (IBS-C): 1831 // Official J. Am. Coll. Gastroenterol. ACG. 2014. Vol. 109. P. S541.
29. Rao S. et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation // Am. J. Gastroenterol. 2012. Vol. 107. N. 11. P. 1714–1724. quiz 1725.
30. Rao S. et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis // Gastroenterol. 2010. Vol. 139. N. 5. P. 1549–1558, 1558.e1.
31. Moayyedi Р. et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS) // J. Can. Assoc. Gastroenterol. 2019. Vol. 2. N. 1. P. 6–29.
32. Efskind P.S., Bernklev Т., Vatn M.H. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome // Scand. J. Gastroenterol. 1996. Vol. 31. N. 5. P. 463–468.
33. Hanauer S.B. The role of loperamide in gastrointestinal disorders // Rev. Gastroenterol. Dis. 2008. Vol. 8. N. 1. P. 15–20.
34. Ford С. et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation // Am. J. Gastroenterol. 2014. Vol. 109. Suppl. 1. P. S2–26. quiz S27.